» Articles » PMID: 34434189

Expanding Horizons in Complement Analysis and Quality Control

Overview
Journal Front Immunol
Date 2021 Aug 26
PMID 34434189
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Complement not only plays a key role in host microbial defense but also modulates the adaptive immune response through modification of T- and B-cell reactivity. Moreover, a normally functioning complement system participates in hematopoiesis, reproduction, lipid metabolism, and tissue regeneration. Because of its powerful inflammatory potential, multiple regulatory proteins are needed to prevent potential tissue damage. In clinical practice, dysregulation and overactivation of the complement system are major causes of a variety of inflammatory and autoimmune diseases ranging from nephropathies, age-related macular degeneration (AMD), and systemic lupus erythematosus (SLE) to graft rejection, sepsis, and multi-organ failure. The clinical importance is reflected by the recent development of multiple drugs targeting complement with a broad spectrum of indications. The recognition of the role of complement in diverse diseases and the advent of complement therapeutics has increased the number of laboratories and suppliers entering the field. This has highlighted the need for reliable complement testing. The relatively rapid expansion in complement testing has presented challenges for a previously niche field. This is exemplified by the issue of cross-reactivity of complement-directed antibodies and by the challenges of the poor stability of many of the complement analytes. The complex nature of complement testing and increasing clinical demand has been met in the last decade by efforts to improve the standardization among laboratories. Initiated by the 14 rounds of external quality assessment since 2010 resulted in improvements in the consistency of testing across participating institutions, while extending the global reach of the efforts to more than 200 laboratories in 30 countries. Worldwide trends of assay availability, usage, and analytical performance are summarized based on the past years' experiences. Progress in complement analysis has been facilitated by the quality assessment and standardization efforts that now allow complement testing to provide a comprehensive insight into deficiencies and the activation state of the system. This in turn enables clinicians to better define disease severity, evolution, and response to therapy.

Citing Articles

Urine complement analysis implies complement activation is involved in membranous nephropathy.

Xu Y, Li Y, Zhang Y, Li G Front Med (Lausanne). 2025; 12:1515928.

PMID: 40018357 PMC: 11865186. DOI: 10.3389/fmed.2025.1515928.


When a NeF Is Not Enough: Improving Assays in C3 Glomerulopathy.

Canetta P J Am Soc Nephrol. 2025; 36(2):174-176.

PMID: 39774057 PMC: 11801742. DOI: 10.1681/ASN.0000000604.


C3 Glomerulopathy: A Current Perspective in an Evolving Landscape.

Magliulo E, Ravipati P Glomerular Dis. 2024; 4(1):200-210.

PMID: 39618492 PMC: 11606624. DOI: 10.1159/000542354.


Impact of Preanalytical Procedures on Complement Biomarkers in Cerebrospinal Fluid and Plasma from Controls and Alzheimer's Disease Patients.

Gutierrez J, Kurz C, Sandoval C, Edmonds R, Bittner T, Perneczky R J Alzheimers Dis. 2024; 101(2):563-576.

PMID: 39213066 PMC: 11492022. DOI: 10.3233/JAD-240287.


A Cell-Based Assay to Measure the Activity of the Complement Convertases.

Stasilojc M, Stasilojc G, Kuzniewska A, Rodriguez de Cordoba S, Okroj M Kidney Int Rep. 2024; 9(7):2260-2268.

PMID: 39081762 PMC: 11284395. DOI: 10.1016/j.ekir.2024.04.058.


References
1.
Parry J, Hwang J, Stahel C, Henderson C, Nadeau J, Stacey S . Soluble terminal complement activation fragment sC5b-9: a new serum biomarker for traumatic brain injury?. Eur J Trauma Emerg Surg. 2020; 47(5):1491-1497. DOI: 10.1007/s00068-020-01407-z. View

2.
Dezfouli M, Bergstrom S, Skattum L, Abolhassani H, Neiman M, Torabi-Rahvar M . Newborn Screening for Presymptomatic Diagnosis of Complement and Phagocyte Deficiencies. Front Immunol. 2020; 11:455. PMC: 7090021. DOI: 10.3389/fimmu.2020.00455. View

3.
Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, Fujihara K . CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder. Heliyon. 2021; 7(1):e05899. PMC: 7809378. DOI: 10.1016/j.heliyon.2021.e05899. View

4.
Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T . Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol. 2020; 40(1):66-81. PMC: 7082388. DOI: 10.1007/s10875-020-00758-x. View

5.
Poppelaars F, Faria B, Gaya DA Costa M, Franssen C, van Son W, Berger S . The Complement System in Dialysis: A Forgotten Story?. Front Immunol. 2018; 9:71. PMC: 5788899. DOI: 10.3389/fimmu.2018.00071. View